Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9Prostatic Neoplasms 8Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Leukemia, Myeloid, Acute 4Hematologic Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Pulmonary Disease, Chronic Obstructive 2Neoplasm Metastasis 2Lymphoma, Follicular 2Leukemia 2Colonic Neoplasms 2COVID-19 2Xerostomia 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Teratoma 1Stroke 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1

Interventions

Ketamine 3Morphine 2Methadone 2resiniferatoxin 1Standard of Care 1Sodium Chloride 1Passive Cutaneous Anaphylaxis 1Hydromorphone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pain, Intractable × Standard of Care × Clear all
NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡